CER Daily Newsfeed

Industry-Funded Study: CBO Underestimated IRA’s Impact On Drug R&D

(9/22, Gabrielle Wanneh, InsideHealthPolicy) reports “A policy brief recently released by the University of Chicago and partially funded by drug maker Gilead suggests that Medicare’s new drug price negotiation authority could lead to a reduction in research & development that translates to 79 fewer small molecule drugs developed and 116 million life years lost over the next two decades.” Subscription Required

Rx Price Controls Mean Hard Choices for Investors

(9/21, John Stanford, RealClearHealth) comments “...Small molecule drugs currently make up 75% of all FDA-approved medications, including some modern blockbusters. Several of the first medicines subject to government price controls are small-molecule drugs that have had significant impacts on disease -- including one that helps lower blood-sugar levels for patients with type 2 diabetes and another that inhibits B-cell proliferation to slow the spread of blood cancers. It's fair to ask whether their developers would have proceeded with these medicines if they had known that their products would be among the first subject to price controls.” Full

After FDA Rejection, Lilly's Ulcerative Colitis Drug Omvoh Picks up Support from England's NICE

(9/22, Eric Sagonowsky, Fierce Pharma) reports “...Friday, England’s National Institute for Health and Care Excellence recommended the drug for the treatment of patients with moderate to severe active ulcerative colitis who can’t tolerate—or haven’t responded to—certain other treatments. The NICE blessing sets up the drug, known in the U.K. as Omvoh, to be the first IL-23p19 inhibitor to be used in NHS England, Lilly said in a release.” Full